Guiyang Xintian Pharmaceutical Co.,Ltd. (SHE:002873)
8.62
-0.11 (-1.26%)
Sep 2, 2026, 3:04 PM CST
SHE:002873 Revenue
Guiyang Xintian Pharmaceutical had revenue of 153.22M CNY in the quarter ending June 30, 2026, a decrease of -7.22%. This brings the company's revenue in the last twelve months to 723.26M, down -6.57% year-over-year. In the year 2025, Guiyang Xintian Pharmaceutical had annual revenue of 749.72M, down -12.57%.
Revenue (ttm)
723.26M
Revenue Growth
-6.57%
P/S Ratio
2.84
Revenue / Employee
521.08K
Employees
1,388
Market Cap
2.05B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 749.72M | -107.83M | -12.57% |
| Dec 31, 2024 | 857.55M | -96.43M | -10.11% |
| Dec 31, 2023 | 953.98M | -133.69M | -12.29% |
| Jan 1, 2023 | 1.09B | 117.83M | 12.15% |
| Jan 1, 2022 | 969.84M | 218.90M | 29.15% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Universal Biotech | 1.15B |
| Zhejiang East Asia Pharmaceutical | 990.47M |
| Guangdong VTR Bio-Tech | 814.07M |
| Jilin Jian Yisheng Pharmaceutical | 650.83M |
| Tiansheng Pharmaceutical Group | 514.89M |
| Suzhou Fushilai Pharmaceutical | 394.29M |
| Yantai Zhenghai Biotechnology | 336.07M |
| Shenzhen Bioeasy Biotechnology | 282.31M |